The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120).
Y. Ito
No relevant relationships to disclose
K. Aogi
No relevant relationships to disclose
N. Masuda
No relevant relationships to disclose
S. Ohno
No relevant relationships to disclose
T. Oda
No relevant relationships to disclose
H. Iwata
Honoraria - Chugai Pharma
M. Kashiwaba
No relevant relationships to disclose
Y. Fujiwara
Honoraria - Abbott Laboratories; Chugai Pharma; Lilly; Sanofi ; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Nippon Kayaku; Pfizer; Taiho Pharmaceutical
S. Kamigaki
No relevant relationships to disclose
T. Ueno
No relevant relationships to disclose
S. Takashima
No relevant relationships to disclose